Dr. Antonio Milici of GeneThera Nominated for National Advisory Committee on Meat & Poultry
30 Janeiro 2009 - 10:00AM
Marketwired
GeneThera, Inc. (PINKSHEETS: GTHR) announced today its President
& CEO, Dr. Antonio Milici, has been nominated for the National
Advisory Committee on Meat & Poultry.
The Committee is part of the USDA's food inspection service.
Nominations for membership are sought from individuals representing
industry, academia, State and local government officials, public
health organizations, and consumers and consumer organizations. The
full committee consists of 16 to 18 members, and each person is
expected to serve a two-year term.
The NACMPI was established in 1971 to the provide advice and
recommendations to the U.S. Secretary of Agriculture on meat and
poultry inspection programs. Membership is drawn from a broad range
of groups interested in food safety including consumers, producers,
processors, exporters and importers of meat and poultry products,
as well as those in academia, public health, and federal and state
government.
GeneThera is exceptionally honored to have its founder and
President nominated for this position.
Dr. Milici had this comment on his nomination: "If I am
appointed to this committee, I will use my position to better
protect the American public from food borne pathogens of all types.
GeneThera is committed to the safety and security of the food that
goes on the plates of all Americans. For too long, we have had to
wonder if the food we are buying from the grocery stores or
restaurants and feeding to our children is truly safe. With the
increased use of antibiotics and supplements in cattle, we have
seen the rise of harmful and often deadly pathogens such as E.Coli.
There was a time that we felt safe eating a rare hamburger, or
eating lettuce without even washing it. Now, the American people
must be cautious with every bit of food or drink we put into our
bodies. Today we are in the midst of the largest outbreak of
salmonella in our history. Too often the victims of these outbreaks
are the extremely young or elderly; those of our nation that are
the weakest. It is time we stand up and take the actions necessary
to protect them. The technology to eliminate many of these
pathogens does exist, we just need some support to bring it to the
forefront."
ABOUT GENETHERA, INC.
GeneThera, Inc. is a molecular biotechnology company located in
Wheat Ridge, Colorado. The Company's proprietary diagnostic
solution is based on a genetic expression assay, GES(TM), a
protocol designed to function on a highly automated Fluorogenic PCR
platform. This platform enables GeneThera to offer tests that are
presently not available from other technologies. The GES is
designed for a host of individual diseases, the current priorities
being Mad Cow disease, E. coli 0157:H7 and Johne's disease. For
more information, contact Dr. Tony Milici MD, PHD at 303-463-6371
or Al Goldsmith of The Goldsmith Group LLC at 303-838-4370.
This press release contains forward-looking statements, which
are made pursuant to the Safe-Harbor provisions of the Private
Securities Litigation Reform Act of 1995. Words such as "intends,"
"believes," and similar expressions reflecting something other than
historical fact are intended to identify forward-looking
statements, but are not the exclusive means of identifying such
statements. These forward-looking statements involve a number of
risks and uncertainties, including the timely development and
market acceptance of products and technologies, the ability to
secure additional sources of finance, the ability to reduce
operating expenses, and other factors described in the Company's
filings with the Securities and Exchange Commission. The actual
results that the Company achieves may differ materially from any
forward-looking statement due to such risks and uncertainties. The
Company undertakes no obligation to revise or update any
forward-looking statements in order to reflect events or
circumstances that may arise after the date of this release.
Contacts: Dr. Tony Milici 303-463-6371 Goldsmith Group
303-838-4370 JR Dopkin & Associates 516-884-3200
GeneThera (CE) (USOTC:GTHR)
Gráfico Histórico do Ativo
De Jun 2024 até Jul 2024
GeneThera (CE) (USOTC:GTHR)
Gráfico Histórico do Ativo
De Jul 2023 até Jul 2024